Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
February 15, 2024 at 4:07 PM EST
Financial Results
- Fourth quarter revenue of
$135.4 million , a 31 percent increase over the same period in 2022 - Full year 2023 revenue of
$482.4 million , a 20 percent increase over 2022 - Reiterated 2024 revenue guidance of
$600 –$630 million - Fourth quarter net income of
$31.4 million , compared to$16.6 million in fourth quarter 2022 - 2023 net income of
$106.1 million , compared to$101.4 million in 2022 - Cash and investments of
$425.4 million as ofDecember 31, 2023
“The medical field is increasingly recognizing that Cushing’s syndrome is much more prevalent than was previously assumed. Our strong 2023 commercial results reflect that physicians are more regularly screening for hypercortisolism. The results demonstrate our ability to support these physicians as they manage this complex disease. We are confident these trends will continue and are reiterating our 2024 revenue guidance of
Corcept’s fourth quarter 2023 revenue was
Diluted net income per common share was
Cash and investments were
Clinical Development
“Our clinical development programs are advancing rapidly and will reach important milestones this year. We are on-track to submit our NDA for relacorilant in Cushing’s syndrome and will report data from our trials in Cushing’s syndrome (GRACE, GRADIENT and CATALYST), ovarian cancer (ROSELLA) and ALS (DAZALS),” added
Cushing’s Syndrome
- GRACE – Phase 3 trial of relacorilant in patients with all etiologies of Cushing’s syndrome – results from open label and randomized withdrawal phases expected in the second quarter
- Relacorilant New Drug Application (NDA) – NDA submission for Cushing’s syndrome expected in the second quarter
- GRADIENT – Phase 3 trial of relacorilant in patients with Cushing’s syndrome caused by adrenal adenomas – enrollment continues; results expected in the second half of this year
- CATALYST – Phase 4 trial examining the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes; patients with hypercortisolism may enter a randomized, double-blind, placebo-controlled study of Korlym – enrollment continues; preliminary prevalence phase results: 24% prevalence rate in the first 700 patients enrolled; final results from prevalence and treatment phases expected by year-end
“We are on-track to submit our relacorilant NDA in the second quarter. Relacorilant has demonstrated tremendous promise as a treatment for patients with Cushing’s syndrome and we are eager to make it more broadly available,” said
“Our CATALYST trial is the largest study ever conducted to establish the prevalence of hypercortisolism in patients with difficult-to-control diabetes. We expect CATALYST’s findings to greatly stimulate physicians’ efforts to screen for hypercortisolism in patients with difficult-to-control diabetes and to treat them when hypercortisolism is found. Almost all of these patients currently go undiagnosed. We believe that CATALYST will be a landmark study and look forward to presenting the final results from the prevalence phase at the American Diabetes Association’s 84th Scientific Sessions in June,” added
Oncology
- ROSELLA – Pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer – enrollment continues; results expected by year-end
- Open-label, Phase 1b trial of relacorilant plus pembrolizumab in patients with adrenal cancer with cortisol excess – enrollment completed; results expected by mid-year
- Randomized, placebo-controlled, Phase 2 trial of relacorilant plus enzalutamide in patients with prostate cancer in collaboration with the
University of Chicago – enrollment continues
“If our ROSELLA trial replicates the results of our Phase 2 trial in patients with platinum-resistant ovarian cancer (results published in
Amyotrophic Lateral Sclerosis (ALS)
- DAZALS – Randomized, double-blind, placebo-controlled, Phase 2 trial of dazucorilant in patients with ALS – enrollment continues; results expected by year-end
“ALS is a lethal illness with an urgent need for better treatment. Dazucorilant showed great promise in animal models of ALS – improving motor performance and reducing neuroinflammation and muscular atrophy. Our DAZALS study is investigating dazucorilant’s potential to significantly improve the lives of patients with ALS. We expect data by the end of this year,” said
Non-alcoholic Steatohepatitis (NASH)
- MONARCH – Randomized, double-blind, placebo-controlled, Phase 2b trial of miricorilant in patients with biopsy-confirmed NASH – enrollment continues
“Miricorilant has the potential to greatly benefit the millions of patients with NASH. Our Phase 1b study demonstrated that miricorilant effectively reduces liver fat, improves liver health and key metabolic and lipid measures and is well-tolerated. We look forward to building on these promising results in our MONARCH study,” said
Conference Call
We will hold a conference call on
About
For over 25 years, Corcept’s focus on cortisol modulation and its potential to treat patients across a wide variety of serious disorders has led to the discovery of more than 1,000 proprietary selective cortisol modulators. Corcept’s advanced clinical trials are being conducted in patients with hypercortisolism, solid tumors, ALS and NASH. In
Forward-Looking Statements
Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations that are subject to risks and uncertainties that might cause our actual results to differ materially from those such statements express or imply. These risks and uncertainties include, but are not limited to, our ability to operate our business; generate sufficient revenue to fund our activities; the availability of competing treatments for hypercortisolism, including generic versions of Korlym; our ability to obtain acceptable prices and adequate insurance coverage and reimbursement for Korlym; risks related to the development of relacorilant, dazucorilant, miricorilant and our other product candidates, including their clinical attributes, regulatory approvals, mandates, oversight and other requirements; the timing, cost and outcome of legal disputes and investigations; and the scope and protective power of our intellectual property. These and other risks are set forth in our
In this press release, forward-looking statements include: our continued revenue growth and 2024 revenue guidance; the rates of screening and treatment of hypercortisolism; cortisol modulation’s potential to treat many serious diseases; development of relacorilant as a treatment for Cushing’s syndrome and ovarian, adrenal and prostate cancer; the design, timing and expectations regarding our GRACE trial; the timing and outcome of relacorilant’s NDA in Cushing’s syndrome; the design, timing and expectations regarding our GRADIENT trial; the design, timing and expectations regarding our CATALYST trial; the timing and expectations of our ROSELLA trial and the potential for relacorilant plus nab-paclitaxel to become a standard of care; the timing and expectations of our DAZALS trial of dazucorilant in patients with ALS; the timing and substance of our MONARCH trial in patients with NASH, and the pace of enrollment, study design and timelines, and the accrual and attributes of clinical data, as well as the timing of regulatory submissions with respect to all of our development activities. We disclaim any intention or duty to update forward-looking statements made in this press release.
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) |
|||||
2023 |
2022(1) |
||||
| (Unaudited) | |||||
| Assets | |||||
| Cash and investments | $ | 425,397 | $ | 436,619 | |
| Trade receivables, net of allowances | 41,123 | 31,057 | |||
| Insurance recovery receivable related to Melucci litigation | 14,000 | 14,000 | |||
| Inventory | 15,974 | 17,031 | |||
| Operating lease right-of-use asset | 120 | 1,143 | |||
| Deferred tax assets, net | 90,605 | 61,465 | |||
| Other assets | 34,298 | 22,115 | |||
| Total assets | $ | 621,517 | $ | 583,430 | |
| Liabilities and Stockholders’ Equity | |||||
| Accounts payable | $ | 17,396 | $ | 11,976 | |
| Accrued settlement related to Melucci litigation | 14,000 | 14,000 | |||
| Operating lease liabilities | 151 | 1,143 | |||
| Other liabilities | 83,265 | 54,469 | |||
| Stockholders’ equity | 506,705 | 501,842 | |||
| Total liabilities and stockholders’ equity | $ | 621,517 | $ | 583,430 | |
| (1) Derived from audited financial statements at that date | |||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (In thousands, except per share data) |
|||||||||||||||
| Three Months Ended | Year Ended | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Revenues | |||||||||||||||
| Product revenue, net | $ | 135,405 | $ | 103,056 | $ | 482,375 | $ | 401,858 | |||||||
| Operating expenses | |||||||||||||||
| Cost of sales | 1,876 | 1,480 | 6,481 | 5,385 | |||||||||||
| Research and development | 54,707 | 36,754 | 184,353 | 130,991 | |||||||||||
| Selling, general and administrative | 47,152 | 42,323 | 184,259 | 152,848 | |||||||||||
| Settlement expense related to Melucci litigation | — | 14,000 | — | 14,000 | |||||||||||
| Insurance recovery related to Melucci litigation | — | (14,000 | ) | — | (14,000 | ) | |||||||||
| Total operating expenses | 103,735 | 80,557 | 375,093 | 289,224 | |||||||||||
| Income from operations | 31,670 | 22,499 | 107,282 | 112,634 | |||||||||||
| Interest and other income | 5,139 | 1,777 | 17,275 | 3,557 | |||||||||||
| Income before income taxes | 36,809 | 24,276 | 124,557 | 116,191 | |||||||||||
| Income tax expense | (5,454 | ) | (7,675 | ) | (18,417 | ) | (14,773 | ) | |||||||
| Net income | $ | 31,355 | $ | 16,601 | $ | 106,140 | $ | 101,418 | |||||||
| Net income attributable to common stockholders | $ | 31,138 | $ | 16,553 | $ | 105,496 | $ | 101,288 | |||||||
| Basic net income per common share | $ | 0.30 | $ | 0.15 | $ | 1.02 | $ | 0.95 | |||||||
| Diluted net income per common share | $ | 0.28 | $ | 0.14 | $ | 0.94 | $ | 0.87 | |||||||
| Weighted-average shares outstanding used in computing net income per common share | |||||||||||||||
| Basic | 102,455 | 107,700 | 103,560 | 106,787 | |||||||||||
| Diluted | 110,886 | 116,328 | 111,742 | 115,966 | |||||||||||
CONTACT:
Investor inquiries:
ir@corcept.com
Media inquiries:
Communications@corcept.com
www.corcept.com
Source: Corcept Therapeutics Incorporated